Última actualización 18 de julio de 2026
Key finding
Adjusted mean reduction in HbA1c from baseline to Week 16 was significantly greater in triple FDC of DAPA+SITA+MET IR (−2.08%) versus dual FDC of SITA+MET IR (−1.38%) P < 0.0001.
This study evaluated the effectiveness of a triple fixed-dose combination of Dapagliflozin, Sitagliptin, and Metformin compared to a dual combination of Sitagliptin and Metformin in managing Type 2 Diabetes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effectiveness of a triple fixed-dose combination of Dapagliflozin, Sitagliptin, and Metformin compared to a dual combination of Sitagliptin and Metformin in managing Type 2 Diabetes.
These findings are clinically significant as they suggest that the triple fixed-dose combination may provide a more effective treatment option for patients with Type 2 Diabetes, potentially leading to better long-term health outcomes. Improved glycemic control can reduce the risk of diabetes-related complications, making this combination an important consideration for clinicians in managing diabetes.
The study's sample size and demographic characteristics may limit generalizability. Only short-term outcomes were assessed at Week 16, limiting long-term efficacy conclusions. The trial did not explore potential side effects or adverse events associated with the triple combination.
Published in
Publication details and source links for this paper.
Mahendra PS, Sandeep G, Manish S, et al. Triple Fixed-Dose Combination of Dapagliflozin, Sitagliptin, and Metformin for Type 2 Diabetes. Advances in Therapy. 2025;42(10):5187-5201. doi:10.1007/s12325-025-03323-3
Triple FDC showed a significantly greater reduction in HbA1c (−2.08%) compared to dual FDC (−1.38%), P < 0.0001.
48.9% of patients on triple FDC achieved HbA1c < 7% versus 31.1% on dual FDC, P = 0.0029.
Change in fasting blood glucose was significantly greater in the triple FDC group (−36.9 mg/dL) compared to dual FDC (−30.6 mg/dL), P < 0.0001.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Glimepiride + voglibose + metformin, Voglibose + metformin and Blood glucose, Body weight, Glucose iAUC (OGTT), and 2 more.
This study contributes evidence to
Primary intervention
Glimepiride + voglibose + metformin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
7
Evidence pairs
732
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Glimepiride + voglibose + metformin → Blood glucose
Glimepiride + voglibose + metformin → Blood glucose
Glimepiride + voglibose + metformin → Body weight
Glimepiride + voglibose + metformin → Body weight
Glimepiride + voglibose + metformin → Glucose iAUC (OGTT)
Glimepiride + voglibose + metformin → Glucose iAUC (OGTT)
Glimepiride + voglibose + metformin → Proportion achieving HbA1c <7.0%
Glimepiride + voglibose + metformin → Proportion achieving HbA1c <7.0%
Voglibose + metformin → Proportion achieving HbA1c <7.0%
Voglibose + metformin → Proportion achieving HbA1c <7.0%
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Glimepiride + voglibose + metformin and Fasting Glucose, Glimepiride + voglibose + metformin and Body Weight.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies on Glimepiride + voglibose + metformin
Contributes to Glimepiride + voglibose + metformin evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Glimepiride + voglibose + metformin appears to improve Blood glucose.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Glimepiride + voglibose + metformin appears to improve Glucose iAUC (OGTT).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Glimepiride + voglibose + metformin appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Glimepiride + voglibose + metformin appears to improve Proportion achieving HbA1c <7.0%.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Proportion achieving HbA1c <7.0%
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
